Skip to content

EVOKE PHARMA, INC.: 10-Q filed 2017-11-14

What EVOKE PHARMA, INC. reported in its quarterly report filed 2017-11-14 (fiscal Q3 2017): 20 published measures, 62 facts as tagged in accession 0001564590-17-023771.

This filing

Form
10-Q (quarterly report)
Filed
2017-11-14
Fiscal period
fiscal Q3 2017
Accession
0001564590-17-023771 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All EVOKE PHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-09-3010,759,247USD
At 2016-12-319,294,330USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2017-09-308,699,560USD
At 2016-12-315,506,692USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-09-302,059,687USD
At 2016-12-313,787,638USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-09-3010,412,968USD
At 2016-12-319,007,071USD
At 2016-09-3010,379,882USD
At 2015-12-318,691,155USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-5,243,061USD92
2017-01-01 to 2017-09-30-11,921,069USD273
2016-07-01 to 2016-09-30-3,025,281USD92
2016-01-01 to 2016-09-30-9,221,188USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-09-30-70,730,212USD
At 2016-12-31-58,809,143USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2017-07-01 to 2017-09-3015,351,295shares92
2017-01-01 to 2017-09-3014,740,977shares273
2016-07-01 to 2016-09-3010,614,692shares92
2016-01-01 to 2016-09-308,341,750shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2017-07-01 to 2017-09-3015,351,295shares92
2017-01-01 to 2017-09-3014,766,853shares273
2016-07-01 to 2016-09-3010,614,692shares92
2016-01-01 to 2016-09-308,341,750shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-0.34USD/shares92
2017-01-01 to 2017-09-30-0.81USD/shares273
2016-07-01 to 2016-09-30-0.29USD/shares92
2016-01-01 to 2016-09-30-1.11USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-0.34USD/shares92
2017-01-01 to 2017-09-30-0.89USD/shares273
2016-07-01 to 2016-09-30-0.29USD/shares92
2016-01-01 to 2016-09-30-1.11USD/shares274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-07-01 to 2017-09-30475,897USD92
2017-01-01 to 2017-09-301,404,926USD273
2016-07-01 to 2016-09-30452,236USD92
2016-01-01 to 2016-09-301,298,279USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-3,701,745USD92
2017-01-01 to 2017-09-30-8,571,548USD273
2016-07-01 to 2016-09-30-2,169,435USD92
2016-01-01 to 2016-09-30-8,220,068USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-09-3010,747,696USD
At 2016-12-319,282,779USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-09-302,648,659USD
At 2016-12-311,411,673USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-07-01 to 2017-09-303,701,745USD92
2017-01-01 to 2017-09-308,571,548USD273
2016-07-01 to 2016-09-302,169,435USD92
2016-01-01 to 2016-09-308,220,068USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-09-3015,413,610shares
At 2016-12-3112,350,360shares

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-09-3011,551USD
At 2016-12-3111,551USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-07-01 to 2017-09-30984,047USD92
2017-01-01 to 2017-09-303,065,595USD273
2016-07-01 to 2016-09-30830,092USD92
2016-01-01 to 2016-09-302,770,500USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-1,541,316USD92
2017-01-01 to 2017-09-30-3,349,521USD273
2016-07-01 to 2016-09-30-855,846USD92
2016-01-01 to 2016-09-30-1,001,120USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2017-01-01 to 2017-09-307,389,101USD273
2016-01-01 to 2016-09-30358,023USD274

Inspect the source

Entity
EVOKE PHARMA, INC. / CIK 0001403708
Captured
2026-09-21T17:19:23.305Z
SEC response SHA-256
1d2ea0edbbb48066d62d49983dacdd25cf55cdf81e3ee5a742e26303a1f7d06e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001403708.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))